Haitian-born physician and entrepreneur Dr. Herriot Tabuteau is making major waves in the biotechnology industry, with his fortune reportedly climbing to $2.2 billion amid the continued rise of the company he founded, Axsome Therapeutics.
Tabuteau founded Axsome Therapeutics in 2012 with a focus on developing treatments for central nervous system disorders, an area of medicine known for complex research challenges and significant unmet patient needs. More than a decade later, the New York-based biotech company has emerged as a major player in the field.
According to recent reporting, shares of Axsome surged over a nine-month period, significantly increasing the value of Tabuteau’s stake in the company and pushing his estimated net worth to approximately $2.2 billion. Because billionaire fortunes tied to publicly traded companies can fluctuate with stock prices, the figure remains an estimate rather than a fixed amount.
The company has also reached a major regulatory milestone involving Auvelity, one of its best-known treatments. Already approved for major depressive disorder, the drug received an additional U.S. Food and Drug Administration approval in 2026 for agitation associated with dementia due to Alzheimer’s disease. The U.S. Food and Drug Administration described the treatment as the first approved non-antipsychotic drug for the condition.
For millions of families affected by Alzheimer’s disease, the development is significant. Agitation can include restlessness, emotional distress, verbal aggression, and other behavioral symptoms that can create serious challenges for patients, caregivers, and healthcare providers.
Tabuteau’s journey to biotech leadership is equally remarkable. Born in Haiti, he later trained at Yale School of Medicine before building experience across medicine and finance. His professional background included work in the financial sector before he launched Axsome with an ambitious focus on treatments for brain and neurological disorders.
The company’s path was not an overnight success. Axsome spent years developing its pipeline before gaining wider attention following key drug approvals and commercial growth. Today, its progress has placed Tabuteau among a small group of Haitian-born entrepreneurs to achieve billionaire status.
For the Haitian community and global diaspora, Tabuteau’s rise represents another powerful example of Haitian excellence across industries that do not always receive widespread visibility.
From Haiti to medicine, finance, and the leadership of a multibillion-dollar biotechnology company, Dr. Herriot Tabuteau’s story is one worth knowing—and one that continues to unfold.
